Robyn Karnauskas
Stock Analyst at Truist Securities
(2.41)
# 2,546
Out of 5,008 analysts
181
Total ratings
42.58%
Success rate
0.47%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robyn Karnauskas
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TRML Tourmaline Bio | Downgrades: Hold | $63 → $48 | $47.89 | +0.24% | 3 | Sep 10, 2025 | |
| ABCL AbCellera Biologics | Maintains: Buy | $28 → $10 | $6.32 | +58.35% | 2 | May 16, 2025 | |
| AMGN Amgen | Maintains: Hold | $333 → $298 | $295.76 | +0.76% | 12 | Jan 8, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $62 → $65 | $44.85 | +44.94% | 2 | Jan 8, 2025 | |
| MRK Merck & Co. | Downgrades: Hold | $130 → $110 | $86.73 | +26.83% | 11 | Jan 8, 2025 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,033 → $1,029 | $851.48 | +20.85% | 5 | Oct 31, 2024 | |
| GILD Gilead Sciences | Maintains: Hold | $82 → $83 | $117.68 | -29.47% | 18 | Aug 15, 2024 | |
| ABBV AbbVie | Reiterates: Buy | $195 → $210 | $232.44 | -9.65% | 8 | Jul 26, 2024 | |
| BMEA Biomea Fusion | Downgrades: Hold | n/a | $1.72 | - | 3 | Jun 11, 2024 | |
| BIIB Biogen | Maintains: Buy | $340 | $150.94 | +125.26% | 17 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 | $1.63 | +1,495.09% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $7 | $1.76 | +298.86% | 13 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,135 | $599.96 | +89.18% | 16 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 | $1.73 | +479.71% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 | $4.21 | +113.78% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $16.12 | +42.68% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $16.34 | +193.76% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $14.84 | +236.93% | 8 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $456 → $508 | $419.16 | +21.19% | 13 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $36 | $25.84 | +39.32% | 5 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $25 | $64.39 | -61.17% | 1 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $2.61 | - | 6 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $140 | $55.00 | +154.55% | 5 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30,000 | $6.00 | +499,900.00% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | $7 | $1.46 | +379.45% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $60.80 | -9.54% | 1 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $500 → $320 | $20.50 | +1,460.98% | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $15 | $14.40 | +4.17% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $3.41 | +633.14% | 1 | Nov 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $85 | $1.03 | +8,152.43% | 1 | Oct 8, 2020 |
Tourmaline Bio
Sep 10, 2025
Downgrades: Hold
Price Target: $63 → $48
Current: $47.89
Upside: +0.24%
AbCellera Biologics
May 16, 2025
Maintains: Buy
Price Target: $28 → $10
Current: $6.32
Upside: +58.35%
Amgen
Jan 8, 2025
Maintains: Hold
Price Target: $333 → $298
Current: $295.76
Upside: +0.76%
Bristol-Myers Squibb Company
Jan 8, 2025
Maintains: Buy
Price Target: $62 → $65
Current: $44.85
Upside: +44.94%
Merck & Co.
Jan 8, 2025
Downgrades: Hold
Price Target: $130 → $110
Current: $86.73
Upside: +26.83%
Eli Lilly and Company
Oct 31, 2024
Maintains: Buy
Price Target: $1,033 → $1,029
Current: $851.48
Upside: +20.85%
Gilead Sciences
Aug 15, 2024
Maintains: Hold
Price Target: $82 → $83
Current: $117.68
Upside: -29.47%
AbbVie
Jul 26, 2024
Reiterates: Buy
Price Target: $195 → $210
Current: $232.44
Upside: -9.65%
Biomea Fusion
Jun 11, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.72
Upside: -
Biogen
May 16, 2024
Maintains: Buy
Price Target: $340
Current: $150.94
Upside: +125.26%
May 15, 2024
Maintains: Buy
Price Target: $26
Current: $1.63
Upside: +1,495.09%
May 13, 2024
Maintains: Buy
Price Target: $8 → $7
Current: $1.76
Upside: +298.86%
Apr 3, 2024
Maintains: Buy
Price Target: $1,135
Current: $599.96
Upside: +89.18%
Mar 26, 2024
Maintains: Buy
Price Target: $10
Current: $1.73
Upside: +479.71%
Mar 26, 2024
Maintains: Buy
Price Target: $9
Current: $4.21
Upside: +113.78%
Mar 25, 2024
Reiterates: Buy
Price Target: $23
Current: $16.12
Upside: +42.68%
Mar 25, 2024
Reiterates: Buy
Price Target: $48
Current: $16.34
Upside: +193.76%
Mar 25, 2024
Reiterates: Buy
Price Target: $50
Current: $14.84
Upside: +236.93%
Jan 31, 2024
Maintains: Buy
Price Target: $456 → $508
Current: $419.16
Upside: +21.19%
Dec 14, 2023
Maintains: Buy
Price Target: $42 → $36
Current: $25.84
Upside: +39.32%
Oct 6, 2023
Downgrades: Hold
Price Target: $25
Current: $64.39
Upside: -61.17%
Oct 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $2.61
Upside: -
Sep 25, 2023
Reiterates: Buy
Price Target: $140
Current: $55.00
Upside: +154.55%
Sep 6, 2023
Reiterates: Buy
Price Target: $30,000
Current: $6.00
Upside: +499,900.00%
Aug 16, 2023
Reiterates: Hold
Price Target: $7
Current: $1.46
Upside: +379.45%
May 11, 2023
Maintains: Buy
Price Target: $65 → $55
Current: $60.80
Upside: -9.54%
Aug 23, 2022
Maintains: Buy
Price Target: $500 → $320
Current: $20.50
Upside: +1,460.98%
Aug 9, 2022
Maintains: Buy
Price Target: $10 → $15
Current: $14.40
Upside: +4.17%
Nov 11, 2020
Initiates: Buy
Price Target: $25
Current: $3.41
Upside: +633.14%
Oct 8, 2020
Initiates: Buy
Price Target: $85
Current: $1.03
Upside: +8,152.43%